npj Breast Cancer

Papers
(The TQCC of npj Breast Cancer is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer292
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies174
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now122
Triple negative breast cancer: Pitfalls and progress115
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group109
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer100
Evolution of HER2-low expression from primary to recurrent breast cancer91
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group87
Immunotherapy for early triple negative breast cancer: research agenda for the next decade66
Immunotherapy in breast cancer: an overview of current strategies and perspectives65
Connected-UNets: a deep learning architecture for breast mass segmentation61
ARe we there yet? Understanding androgen receptor signaling in breast cancer57
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer51
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment47
Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis46
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy44
PARP inhibition in breast cancer: progress made and future hopes42
Large language model (ChatGPT) as a support tool for breast tumor board42
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer41
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic40
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment38
The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients37
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer36
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma36
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis33
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge33
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer33
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer32
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL31
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups31
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort31
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer30
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer30
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis30
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer30
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors30
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes29
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer28
Clinical utility of genomic signatures in young breast cancer patients: a systematic review27
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer27
The genomic landscape of metastatic histologic special types of invasive breast cancer27
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study26
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study26
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis26
Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer26
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions25
Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer25
A careful reassessment of anthracycline use in curable breast cancer25
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation25
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer25
Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients24
Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer24
Characterization of weaning-induced breast involution in women: implications for young women’s breast cancer24
Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes24
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk23
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer22
Retinoblastoma protein expression and its predictors in triple-negative breast cancer22
The clinical and molecular significance associated with STING signaling in breast cancer22
Allostatic load: a framework to understand breast cancer outcomes in Black women21
Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML21
The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data21
A randomized intervention involving family to improve communication in breast cancer care21
Subclonal heterogeneity and evolution in breast cancer21
An emerging generation of endocrine therapies in breast cancer: a clinical perspective20
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression20
Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome20
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies20
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients20
Integrative multiomics-histopathology analysis for breast cancer classification20
Effects of systemic inflammation on relapse in early breast cancer20
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study20
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer19
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies19
Using whole-genome sequencing data to derive the homologous recombination deficiency scores19
Histopathologic, immunophenotypic, and proteomics characteristics of low-grade phyllodes tumor and fibroadenoma: more similarities than differences19
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial19
MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer19
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations19
Oncogene-mediated metabolic gene signature predicts breast cancer outcome19
Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway18
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-118
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer17
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE17
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases17
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy17
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity17
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer17
Deep learning models for histologic grading of breast cancer and association with disease prognosis17
Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome17
The human intermediate prolactin receptor is a mammary proto-oncogene17
Unmasking the immune microecology of ductal carcinoma in situ with deep learning16
Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype16
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer16
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial16
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients16
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer16
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer16
Oncogenic action of the exosome cofactor RBM7 by stabilization of CDK1 mRNA in breast cancer16
Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis15
Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study15
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies15
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer15
Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women15
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer15
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer15
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality15
Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites14
Unique cellular protrusions mediate breast cancer cell migration by tethering to osteogenic cells14
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America14
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-614
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis14
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials14
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis13
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer13
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study13
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness13
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants13
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer13
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer13
De-escalation in breast cancer surgery13
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer13
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis13
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing13
0.025366067886353